Dexmedetomidine reduces long-term potentiation in mouse hippocampus

Area of Science:

• Neuroscience
• Pharmacology
• Synaptic Plasticity

Background:

• Dexmedetomidine is an alpha2-adrenergic agonist with sedative properties.
• Its effects on synaptic plasticity, crucial for memory, remain unestablished.
• This study investigates dexmedetomidine's impact on hippocampal synaptic plasticity.

Purpose of the Study:

• To determine the effect of dexmedetomidine on long-term potentiation (LTP) and paired-pulse facilitation in the mouse hippocampus.
• To elucidate the specific receptors involved in dexmedetomidine's action on synaptic plasticity.

Main Methods:

• Extracellular field excitatory postsynaptic potentials (fEPSPs) were recorded in CA1 region of mouse hippocampal slices.
• Schaffer collateral stimulation was used to induce and measure synaptic transmission.
• Effects of dexmedetomidine and various receptor antagonists on LTP were assessed.

Main Results:

• Dexmedetomidine dose-dependently attenuated LTP with an IC50 of 28.6 nm.
• The inhibitory effect was blocked by idazoxan (imidazoline type 2 receptor and alpha2-adrenoceptor antagonist) but not by antagonists for alpha2, imidazoline type 1, alpha1, or GABA-A receptors.
• Selective imidazoline type 2 receptor ligands affected LTP, while dexmedetomidine did not alter paired-pulse facilitation.

Conclusions:

• Dexmedetomidine impairs hippocampal LTP via a mechanism involving imidazoline type 2 receptors and alpha2-adrenoceptors.
• This finding provides insight into the neurobiological effects of dexmedetomidine beyond its sedative actions.